Palleon Pharmaceuticals

Palleon Pharmaceuticals

Biotechnology Research

Waltham, Massachusetts 6,352 followers

Clinical-stage biotech company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases

About us

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Waltham, Massachusetts
Type
Privately Held
Founded
2016
Specialties
Biotechnology, Immuno-Oncology, Clinical Development, and Glyco-Immune Checkpoint Inhibitors

Locations

Employees at Palleon Pharmaceuticals

Updates

Similar pages

Browse jobs

Funding